NuVasive (NSDQ:NUVA) said this week it inked a strategic partnership deal with spinal and extremity surgery tech company Biedermann Technologies.
Through the deal, NuVasive was granted license to Donaueschingen, Germany-based Biedermann Tech’s spinal technology platform intellectual property.
San Diego-based NuVasive said that it will integrate Biedermann’s proprietary screw technology into its Reline portfolio. The combined tech system is expected to be commercially available to surgeons during the first half of next year.
“Partnering with Biedermann Technologies —a highly innovative medical device design powerhouse—coupled with NuVasive’s best-in-class engineering teams and innovation prowess—will accelerate the development and time-to-market to put the most advanced posterior fixation solutions in the hands of our surgeon partners. This partnership will help create better, more reproducible clinical outcomes in some of the hardest to treat spine pathologies, and further demonstrates our commitment to R&D investments to create the future of leading complex spinal innovation,” NuVasive corp dev, strategy & tech exec VP Matt Link said in a prepared release.
Biedermann will also provide services related to the development of its next-gen Reline complex spine system looking to improve upon surgical efficiency, operative reliability and procedural versatility.
“Significant challenges demand smart collaborations. And reconstructive spine surgery of complex deformities and instabilities of all age groups is still such a significant clinical challenge. With this in mind, I welcome the opportunity to work with NuVasive’s very talented and skilled organization to offer clinically meaningful solutions to the global spine community,” Biedermann Technologies founder & prez Lutz Biedermann said in a press release.
Last month, NuVasive said that it launched three new products as part of its biologics portfolio, including its Traditional Bone Allograft, Amniotic Membrate DS and Propel DBM.
